ALK-Positive Lung Non-Small Cell Carcinoma

ALK-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04979988	Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients	completed	—	51	PfizerINDUSTRY	1	Apr 5, 2024	clinicaltrials
NCT04647110	Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.	completed	—	549	PfizerINDUSTRY	1	Apr 6, 2023